Open Orphan plc announced a new contract, valued at £4 million, with a top 3 global pharmaceutical company to be the sponsor of and provide a respiratory syncytial virus (RSV) human challenge study trial. This new £4 million contract represents continued conversion of Open Orphan's substantial pipeline and generation of significant cash flow. The contract further validates Open Orphan's position as the world leader in the provision of viral challenge study clinical trials and laboratory services supporting both biotech and Big Pharma in developing antivirals, vaccines and respiratory therapeutics.